189 related articles for article (PubMed ID: 11426792)
1. Emergent operation for percutaneous coronary rupture after abciximab administration.
Roberts CS; Bocanegra NR
Ann Thorac Surg; 2001 Jun; 71(6):2024-6. PubMed ID: 11426792
[TBL] [Abstract][Full Text] [Related]
2. Coronary perforation during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade: an algorithm for percutaneous management.
Dippel EJ; Kereiakes DJ; Tramuta DA; Broderick TM; Shimshak TM; Roth EM; Hattemer CR; Runyon JP; Whang DD; Schneider JF; Abbottsmith CW
Catheter Cardiovasc Interv; 2001 Mar; 52(3):279-86. PubMed ID: 11246236
[TBL] [Abstract][Full Text] [Related]
3. Glycoprotein IIb/IIIa inhibitors, surgery and bleeding.
Aylward P
Aust N Z J Med; 1998 Oct; 28(5):583-4. PubMed ID: 9847944
[No Abstract] [Full Text] [Related]
4. Bleeding events with abciximab in acute coronary syndromes without early revascularization: An analysis of GUSTO IV-ACS.
Lenderink T; Boersma E; Ruzyllo W; Widimsky P; Ohman EM; Armstrong PW; Wallentin L; Simoons ML;
Am Heart J; 2004 May; 147(5):865-73. PubMed ID: 15131544
[TBL] [Abstract][Full Text] [Related]
5. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting.
Topol EJ; Mark DB; Lincoff AM; Cohen E; Burton J; Kleiman N; Talley D; Sapp S; Booth J; Cabot CF; Anderson KM; Califf RM
Lancet; 1999 Dec; 354(9195):2019-24. PubMed ID: 10636365
[TBL] [Abstract][Full Text] [Related]
6. A randomized two-by-two comparison of high-dose bolus tirofiban versus abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary revascularization and stent placement: the tirofiban evaluation of novel dosing versus abciximab with clopidogrel and inhibition of thrombin (TENACITY) study trial.
Moliterno DJ;
Catheter Cardiovasc Interv; 2011 Jun; 77(7):1001-9. PubMed ID: 21598351
[TBL] [Abstract][Full Text] [Related]
7. Bleeding risks with abciximab after full-dose thrombolysis in rescue or urgent angioplasty for acute myocardial infarction.
Jong P; Cohen EA; Batchelor W; Lazzam C; Kreatsoulas C; Natarajan MK; Strauss BH
Am Heart J; 2001 Feb; 141(2):218-25. PubMed ID: 11174335
[TBL] [Abstract][Full Text] [Related]
8. Massive pulmonary hemorrhage in a patient treated with a platelet glycoprotein IIb/IIIa inhibitor.
Sitges M; Villa FP
Int J Cardiol; 1997 Dec; 62(3):269-71. PubMed ID: 9476687
[TBL] [Abstract][Full Text] [Related]
9. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.
Topol EJ; Moliterno DJ; Herrmann HC; Powers ER; Grines CL; Cohen DJ; Cohen EA; Bertrand M; Neumann FJ; Stone GW; DiBattiste PM; Demopoulos L;
N Engl J Med; 2001 Jun; 344(25):1888-94. PubMed ID: 11419425
[TBL] [Abstract][Full Text] [Related]
10. Emergency coronary bypass grafting for failed percutaneous coronary artery stenting: increased costs and platelet transfusion requirements after the use of abciximab.
Alvarez JM
J Thorac Cardiovasc Surg; 1998 Feb; 115(2):472-3. PubMed ID: 9475547
[No Abstract] [Full Text] [Related]
11. Benefit of bolus-only platelet glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: insights from the very early outcomes in the Evaluation of 7E3 for the Prevention of Ischemic Complications (EPIC) trial.
Marmur JD; Mitre CA; Barnathan E; Cavusoglu E
Am Heart J; 2006 Nov; 152(5):876-81. PubMed ID: 17070148
[TBL] [Abstract][Full Text] [Related]
12. Usefulness of platelet glycoprotein IIb/IIIa inhibitors in coronary stenting for reconstruction of complex lesions: procedural and 30 day outcome.
Galassi AR; Russo G; Nicosia A; Tamburino C; Foti R; Rodi G; Calvi V; Gulizia G; Distefano G; Moshiri S; Giuffrida G
Cardiologia; 1999 Jul; 44(7):639-45. PubMed ID: 10476589
[TBL] [Abstract][Full Text] [Related]
13. Standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization. PROLOG Investigators.
Lincoff AM; Tcheng JE; Califf RM; Bass T; Popma JJ; Teirstein PS; Kleiman NS; Hattel LJ; Anderson HV; Ferguson JJ; Cabot CF; Anderson KM; Berdan LG; Musco MH; Weisman HF; Topol EJ
Am J Cardiol; 1997 Feb; 79(3):286-91. PubMed ID: 9036746
[TBL] [Abstract][Full Text] [Related]
14. Reduced thrombus burden with abciximab delivered locally before percutaneous intervention in saphenous vein grafts.
Barsness GW; Buller C; Ohman EM; Schechter E; Pucillo A; Taylor MA; Miller MJ; Reiner JS; Churchill D; Chandler AB; Gonzalez M; Smith J; Tommaso C; Berdan LG; Wildermann NM; Hasdai D; Holmes DR
Am Heart J; 2000 May; 139(5):824-9. PubMed ID: 10783216
[TBL] [Abstract][Full Text] [Related]
15. Glycoprotein IIb/IIIa receptor inhibition with abciximab during percutaneous coronary interventions increases the risk of bleeding in patients with impaired renal function.
Pinkau T; Ndrepepa G; Kastrati A; Mann JF; Schulz S; Mehilli J; Schömig A
Cardiology; 2008; 111(4):247-53. PubMed ID: 18434733
[TBL] [Abstract][Full Text] [Related]
16. Abciximab readministration.
Orford JL; Holmes DR
Rev Cardiovasc Med; 2002; 3(2):67-70. PubMed ID: 12447149
[TBL] [Abstract][Full Text] [Related]
17. Pronounced benefit of coronary stenting and adjunctive platelet glycoprotein IIb/IIIa inhibition in complex atherosclerotic lesions.
Cura FA; Bhatt DL; Lincoff AM; Kapadia SR; L'Allier PL; Ziada KM; Wolski KE; Moliterno DJ; Brener SJ; Ellis SG; Topol EJ
Circulation; 2000 Jul; 102(1):28-34. PubMed ID: 10880411
[TBL] [Abstract][Full Text] [Related]
18. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization.
EPILOG Investigators
N Engl J Med; 1997 Jun; 336(24):1689-96. PubMed ID: 9182212
[TBL] [Abstract][Full Text] [Related]
19. Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement.
Gawaz M; Ruf A; Neumann FJ; Pogátsa-Murray G; Dickfeld T; Zohlnhöfer D; Schömig A
Thromb Haemost; 1998 Dec; 80(6):994-1001. PubMed ID: 9869173
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of abciximab readministration in coronary intervention.
Madan M; Kereiakes DJ; Hermiller JB; Rund MM; Tudor G; Anderson L; McDonald MB; Berkowitz SD; Sketch MH; Phillips HR; Tcheng JE
Am J Cardiol; 2000 Feb; 85(4):435-40. PubMed ID: 10728946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
